StreetInsider.com News Articles

Incyte to present six oncology studies at ESMO Congress 2026

Fri, 17 Jul 2026 13:11:43 -0400

Incyte (Nasdaq: INCY) will present data from six programs in its oncology portfolio at the European Society for Medical Oncology Congress 2026, scheduled for October 23–27 in Madrid, according to a company statement.

Four of the six presentations will be rapid oral sessions, covering investigational compounds across solid tumor indications. These include two presentations on INCB161734, an oral KRAS G12D inhibitor being studied as monotherapy or in combination with cetuximab in advanced colorectal cancer, and in combination with chemotherapy in advanced pancreatic ductal adenocarcinoma (PDAC). Both colorectal and PDAC indications are also being evaluated in ongoing Phase 3 programs.

A third rapid

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Fri, 17 Jul 2026 13:10:00 -0400

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio

Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026,

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Fri, 17 Jul 2026 13:10:00 -0400

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio

Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Fri, 17 Jul 2026 13:10:00 -0400

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio

Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Fri, 17 Jul 2026 13:10:00 -0400

Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio

Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively

Form 144 INCYTE CORP Filed by: Stein Steven H

Thu, 16 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260716/26779883.html

Form 144 INCYTE CORP Filed by: Stein Steven H

Thu, 16 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260716/26779883.html

Form 4 INCYTE CORP For: Jul 14 Filed by: Mayes Patrick A

Thu, 16 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260716/26779724.html

Form 4 INCYTE CORP For: Jul 14 Filed by: Mayes Patrick A

Thu, 16 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260716/26779724.html

Form 4 INCYTE CORP For: Jul 14 Filed by: CAGNONI PABLO J

Thu, 16 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260716/26779731.html

Form 4 INCYTE CORP For: Jul 14 Filed by: CAGNONI PABLO J

Thu, 16 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260716/26779731.html

Form 4 INCYTE CORP For: Jul 15 Filed by: Issa Mohamed Khairie